Skip to main content

Arvinas, Inc.

ARVN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001655759

No open-market purchases or sales by Arvinas, Inc. insiders were filed in the last 90 days; 201 institutions reported holding it in 13F filings for Q2 2026, worth $468.7M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Arvinas, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Arvinas, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Arvinas, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Norwalk Leslie VDirector41,572Jun 26, 20261
Cunningham EverettDirector41,572Jun 26, 20261
Bain LindaDirector41,572Jun 26, 20261
Smaldone Alsup LaurieDirector41,572Jun 26, 20261
Morrison BriggsDirector111,548Jun 26, 20262
Kennedy Edward Moore Jr.Director54,957Jun 26, 20261
Saik AndrewChief Financial Officer187,432Jun 24, 20264
Cacace Angela MChief Scientific Officer180,390Jun 18, 20265
Teel RandyPresident and CEO285,009May 22, 20265
Berkowitz NoahChief Medical Officer191,395May 13, 20264
Loomis David KVP, Chief Accounting Officer40,193May 13, 20265
Houston John GDirector1,122,183Mar 2, 20261
Agarwal SunilDirector30,166Jun 30, 20250
Young John DDirector26,045Jun 27, 20250
Taylor IanPresident, R&D159,121Feb 25, 20250
Cassidy Sean AChief Financial Officer181,916Feb 27, 20240
Peck RonaldChief Medical Officer67,516Feb 27, 20240
Dixon Wendy LDirector9,121Jun 20, 20230
Shannon Timothy MDirector1,653,128IndirectJun 21, 20220
Ratcliffe LiamDirector185,686IndirectJun 21, 20220
Margus Bradley AlbertDirector2,000IndirectJun 21, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 9, 2021 (view filing)Nov 54 daysRatcliffe LiamDirectorSSale−24.9K$91.30−$2.28M−100.0%0 after6 lots
Nov 9, 2021 (view filing)Nov 5-94 daysRatcliffe LiamDirectorSSale−147.2K$93.31−$13.7M−17.9%675.7K after12 lots
Nov 3, 2021 (view filing)Nov 12 daysHouston John GPresident and CEOSSale−40.0K$88.14−$3.53M−4.6%832.3K after3 lots
Sep 27, 2021 (view filing)Sep 3-724 daysLateShannon Timothy MDirectorSSale−68.8K$87.42−$6.01M−4.0%1.65M after6 lots
Sep 27, 2021 (view filing)Aug 31-Sep 227 daysLateShannon Timothy MDirectorSSale−190.6K$86.26−$16.4M−10.0%1.72M after8 lots
Sep 27, 2021 (view filing)Aug 26-3032 daysLateShannon Timothy MDirectorSSale−115.6K$85.72−$9.91M−5.7%1.91M after7 lots
Sep 27, 2021 (view filing)Aug 23-2535 daysLateShannon Timothy MDirectorSSale−25.1K$85.95−$2.15M−1.2%2.03M after4 lots
Aug 27, 2021 (view filing)Aug 25-262 daysMargus Bradley AlbertDirectorSSale−29.9K$85.01−$2.55M−93.7%2.00K after2 lots
Aug 18, 2021 (view filing)Aug 162 daysTaylor IanChief Scientific OfficerSSale−20.0K$87.30−$1.75M−20.3%78.6K after3 lots
Aug 16, 2021 (view filing)Aug 124 daysPeck RonaldChief Medical OfficerSSale−1.36K$90.54−$123.4K−20.1%5.40K after
Aug 13, 2021 (view filing)Aug 11-132 daysMargus Bradley AlbertDirectorSSale−10.8K$90.03−$974.8K−25.3%31.9K after2 lots
Aug 4, 2021 (view filing)Aug 22 daysHouston John GPresident and CEOSSale−45.9K$97.83−$4.49M−5.3%827.6K after5 lots
Jul 30, 2021 (view filing)Jul 282 daysCassidy Sean AChief Financial OfficerSSale−17.2K$100.00−$1.72M−9.8%158.2K after
Jul 2, 2021 (view filing)Jun 302 daysPeck RonaldChief Medical OfficerSSale−20.0K$76.69−$1.53M−87.9%2.75K after